35265-83-9

Basic information

• Product Name: 2,4-Dichloro-7-methylthieno[3,2-d]pyrimidine
• Synonyms: 2,4-Dichloro-7-methylthieno[3,2-d]pyrimidine;Thieno[3,2-d]pyriMidine, 2,4-dichloro-7-Methyl-;2,4-Dichloro-7-methylthieno[3,2-d]pyrimidine-3
• CAS NO: 35265-83-9
• Molecular Formula: C₇H₄Cl₂N₂S
• Molecular Weight: 219.09
• Product Categories: Heterocycle-Pyrimidine series
• Mol File: 35265-83-9.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 293℃
• Flash Point: 131℃
• Appearance: /
• Density: 1.568
• Vapor Pressure: 0.00308mmHg at 25°C
• Refractive Index: 1.688
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -0.48±0.40(Predicted)
• CAS DataBase Reference: 2,4-Dichloro-7-methylthieno[3,2-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-Dichloro-7-methylthieno[3,2-d]pyrimidine(35265-83-9)
• EPA Substance Registry System: 2,4-Dichloro-7-methylthieno[3,2-d]pyrimidine(35265-83-9)

Safety Data

• Hazardous Substances Data: 35265-83-9(Hazardous Substances Data)

Usage

General Description

The chemical 2,4-Dichloro-7-methylthieno[3,2-d]pyrimidine is an organic compound with the molecular formula C6H3Cl2N3S. It is a heterocyclic compound that contains both chlorine and a methyl group. 2,4-Dichloro-7-methylthieno[3,2-d]pyrimidine is used as a building block in the synthesis of pharmaceuticals and agrochemicals. It is also used as an intermediate in the production of dyes, pigments, and other organic compounds. The 2,4-Dichloro-7-methylthieno[3,2-d]pyrimidine has potential applications in the field of medicinal chemistry and is under research for its biological properties and therapeutic uses.

InChI:InChI=1/C7H4Cl2N2S/c1-3-2-12-5-4(3)10-7(9)11-6(5)8/h2H,1H3

Upstream product

• 35265-81-7 7-methylthieno[3,2-d]pyrimidine-2,4-diol 
• 57-13-6 urea 
• 85006-31-1 3-amino-4-methyl-2-thiophenecarboxylic acid methyl ester 
• 35265-81-7 7-methylthieno<3,2-d>pyrimidine-2,4-dione 

Downstream Products

• 221043-63-6 2-Chloro-4-(trans-cinnamylamino)-7-methylthieno[3,2-d] pyrimidine 
• 35265-88-4 4-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)morpholine 
• 1356016-35-7 2-chloro-thieno[3,2-d]pyrimidine-7-carbaldehyde 
• 1356017-09-8 2-Chloro-thieno[3,2-d]pyrimidine-7-carboxylic acid (3,4-dimethoxy-phenyl)-amide 
• 1356017-78-1 2-chloro-thieno[3,2-d]pyrimidine-7-carboxylic acid (3,4,5-trimethoxy-phenyl)-amide 
• 955979-02-9 2-chloro-7-methyl-4-morpholinothieno[3,2-d]-pyrimidine-6-carbaldehyde 
• 1356017-12-3 2-chloro-thieno[3,2-d]pyrimidine-7-carboxylic acid(2,4-dimethoxy-phenyl)-amide 
• 1024603-90-4 2-chloro-4-(mesityloxy)-7-methylthieno[3,2-d]pyrimidine 
• 221043-41-0 2-Chloro-4-cyclohexylamino-7-methylthieno[3,2-d] pyrimidine 
• 221043-39-6 4-benzylamino-2-chloro-7-methylthieno[3,2-d]pyrimidine 

Relevant articles and documents

Discovery of novel and potent PARP/PI3K dual inhibitors for the treatment of cancer

PARP inhibitors have achieved great success in cancers with BRCA mutations, but only a small portion of patients carry BRCA mutations, which results in their narrow indication spectrum. Recently, emerging evidence has demonstrated that combinations of PARP and PI3K inhibitors could evoke unanticipated synergistic effects in various cancers, even including BRCA-proficient ones. In this work, a series of PARP/PI3K dual inhibitors were designed, synthesized, and evaluated for their biological activities. It was found that compounds 9a and 23a exhibited excellent inhibitory activities against PARP-1 (9a: IC50 = 1.57 nM, 23a: IC50 = 0.91 nM) and PI3Kα (9a: IC50 = 2.0 nM, 23a: IC50 = 1.5 nM), and showed promising antiproliferative activities against both BRCA-deficient (HCT-116, HCC-1937) and BRCA-proficient (SW620, MDA-MB-231/468) tumor cells. 9a and 23a also exhibited considerable in vivo antitumor efficacy in an MDA-MB-468 xenograft mouse model, with TGI values of 56.39% and 48.77%, respectively. Additionally, 23a possessed promising profiles including high kinase selectivity and low cardiotoxicity. Overall, this work indicates 9a and 23a might be potential PARP/PI3K dual inhibitors for cancer therapy and deserve further research.

PYRIMIDINE AMIDE COMPOUNDS AND USE THEREOF

Disclosed are compounds of formula (I) below or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof: (I), in which each of variables each of variables R, R1, R2, X1, X2, X3 and n is defined herein. Also disclosed is a method for treating a cancer with a compound of formula (I) or a salt thereof and a pharmaceutical composition containing same.

Discovery of an Orally Active and Long-Acting DPP-IV Inhibitor through Property-Based Optimization with an in Silico Biotransformation Prediction Tool

Long-acting dipeptidyl peptidase IV inhibitors have emerged as promising molecules for interventions for type 2 diabetes. Once weekly dosing brings greater patient compliance and more stable glycemic control. Starting from our previous highly potent compound with a thienoprimidine scaffold, which is unfortunately severely hit by hepatic biotransformation, a lead compound was rapidly generated by drawing on the experience of our previously discovered long-acting compounds with pyrrolopyrimidine scaffold. With the aid of an in silico biotransformation prediction tool, (R)-2-((2-(3-aminopiperidin-1-yl)-4-oxo-6-(pyridin-3-yl)thieno[3,2-d]pyrimidin-3(4H)-yl)methyl)-4-fluorobenzonitrile was eventually generated and determined to have high potency, a fine pharmacokinetic profile, and a long-acting in vivo efficacy.